Fresenius Medical Care Fresenius Kabi Fresenius Helios Fresenius Vamed
in new markets - Fresenius Medical Care
for further growth - Fresenius Kabi
for better health - Fresenius Helios
for greater efficiency - Fresenius Vamed
close

Seizing opportunities > in new markets

Asia is an important growth market for Fresenius Medical Care. Approximately 620,000 patients with chronic kidney failure are currently being treated in this region, and every year this number increases by about 10 to 11%. We will continue to take advantage of this growth potential. The significant demand for dialysis services offers substantial opportunities to expand our network of clinics in the Asian countries.

In 2008, Fresenius Medical Care achieved sales of US$ 606 million in the Asia-Pacific region. Our goal is to continue our strong organic growth and to increase sales to more than US$ 800 million in constant currency by 2010.

FRESENIUS MEDICAL CARE IN ASIA
  2008 2007 Change
Sales (in million US$) 606 541 12%
Employees (December 31) 3,558 3,095 15%
Dialysis patients (December 31) 9,158 7,789 18%
Dialysis treatments (million) 1.34 1.21 11%
Dialysis clinics (December 31) 125 105 19%
 

READ MORE ABOUT FRESENIUS MEDICAL CARE >>

close
in new markets - Fresenius Medical Care
close

Seizing opportunities > for further growth

With the acquisition of APP Pharmaceuticals, Fresenius Kabi has achieved a leading position in the global market for intravenously administered generic drugs. APP Pharmaceuticals has a strong drug registration portfolio pending and over 70 products under development, opening up new growth opportunities.

At the same time, we are seizing the opportunity of introducing selected Kabi products into the US, with initial focus on parenteral nutrition. We are also planning to launch selected APP IV drugs outside the US.

APP PHARMACEUTICALS IN FIGURES
  2008
Sales US$ 777 million
EBITDA, adjusted* US$ 317 million
EBITDA margin, adjusted* 40.8%
Employees (December 31, full-time equivalent) 1,487
Production facilities 3
Produkte >100
Number of products ~17%
 

READ MORE ABOUT FRESENIUS KABI >>

close
for further growth - Fresenius Kabi
close

Seizing opportunities > for better health

At Fresenius Helios, our commitment is to provide the highest medical quality and care. We aim to offer advanced and proven best-in-class diagnosis and treatment methods for the benefit of our patients. We continuously invest in high-quality, state-of-the-art medicine, and aim to measure and improve the quality of medical care.

Our target ist that our quality indicators should be better than the German average. With a mortality rate of SMR < 1, this was accomplished, among others, for major illnesses shown below.

HELIOS QUALITY INDICATORS
Indications/
standardized mortality rate (SMR)*
2008
SMR
2007
SMR
Acute myocardial infarction 0.73 0.79
Heart failure 0.73 0.85
Stroke 0.83 1.01
Acute cerebral infarction 0.81 0.99
Pneumonia 0.71 0.85
 

READ MORE ABOUT FRESENIUS HELIOS >> 

close
for better health - Fresenius Helios
close

Seizing opportunities > for greater efficiency

Fresenius Vamed is a leading international provider of services in the planning, construction, and management of health care facilities. Our complete value chain and our more than 25 years of international experience are key to providing effective support for hospitals at every stage of their life cycle, and thus contributing towards their successful operating performance. For us, each project is another opportunity to prove our competence.

Hospitals face the dual challenge of increasing efficiency and reducing expenditure. We support hospitals by offering comprehensive process know-how and by taking over medical-technical services and management functions.

VAMED SERVICES
   
Service contracts* for   140 clinics
  ~ 50,000 beds
among others:  
Vienna General Hospital and University Clinics (AKH) ~ 2,100 beds
Charité Hospital Berlin ~ 3,200 beds
University Clinic Hamburg-Eppendorf ~1,370 beds
Prince Court Medical Center, Kuala Lumpur ~ 330 beds
Al Ain Hospital, Abu Dhabi ~ 450 beds
 

READ MORE ABOUT FRESENIUS VAMED >>

close
for greater efficiency - Fresenius Vamed
  • Print page
  • Save as PDF
  • Add to Cart
  • Recommend Page
Home arrow Fresenius Group arrow Fresenius Shares arrow Share Price Development

Print

In 2008, the stock markets were marked by the international financial market crisis and its impact on the real economy. In the course of the year, all stocks were buffeted by these events – resulting, in part, in correspondingly high share price losses. Despite the Fresenius Group’s excellent financial results, neither the ordinary shares nor the preference shares were able to bypass this development.

STOCK MARKETS

The equity markets experienced strong price fluctuations in the first half of 2008. Although supported at first by the good company results released in the reporting season, the equity markets were not able to escape from the continuing turbulences on the money and credit markets. As early as January 2008, at 7,949 points, the DAX registered what would be its high for the year. By May 2008, the MDAX reached 10,069 points – its high for the year. From midyear, the effects of the financial crisis in the United States – triggered by the credit crisis on the US subprime mortgage market – spilled over with full force to the international capital markets. This led to a downward trend that persisted to the end of 2008. Despite the launch of global economic support programs for the industrial sector and huge rescue packages for banks, investors lost confidence. To limit their risks, many withdrew their capital from the stock market, leading to correspondingly high losses in stock prices and indices. The DAX lost heavily in the second half of the year, falling to 4,127 points in November 2008. At its low of 4,735 points in November the MDAX had lost over 50% in value. Both indices recovered slightly by the end of the year but remained well below their levels at the beginning of 2008; the DAX and MDAX closed the year at 4,810 points and 5,602 points, respectively. Over the year the DAX lost 40% and the MDAX 43%. Despite the heavy losses, the DAX still did well compared to other European blue chip indices. The EuroStoxx 50 suffered considerable losses in 2008 with a decrease of 44%. The European Dow Jones STOXX 600 Index, which comprises Europe’s 600 largest companies, closed the year at 197 points, a decrease of 45%. In this index the best performing sectors were Healthcare (-18%), Food&Beverages (-30%), and Telecommunications (-36%), while Banks (-64%), Basic Resources (-64%), and Financial Services (-55%) were the three worst performers. The leading US indices also lost heavily. The S&P 500 closed 2008 with a loss of 38%, while the Dow Jones Industrial Average fell 34%.

Relative Share Price Performance